



XTACY Therapeutics Corporate Update

Vancouver: October 8, 2024 – Xtacy Therapeutics Corp. (CSE: XTCY) (Frankfurt: TT5) (OTC: XTCYF) (“the Company) is pleased to announce updates to its Board of Directors. Ashleigh Vogstad is stepping down from the Board, and Vanni Barbon has been appointed as a Director and the new Audit Chair.

Mr. Barbon's professional experience is extensive; as a BMO Commercial Branch Manager, Investment Analyst, and a public company Chief Financial Officer. “We are thrilled to welcome Vanni to the Company, as his banking and public market expertise will be a tremendous asset to the team,” commented Meris Kott, Xtacy, CEO.

“On behalf of the Board and management, I would like to thank Ashleigh for her exceptional service and contributions to the Company. We look forward to her continued advice when possible,” added Kott.

About Xtacy Therapeutics Corp. :

Xtacy is a prospect generator that provides high-growth companies with financial, operational, and management assistance in the fast-growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies and their clinical studies and trials.

For further information visit website:

www.xtacytherapeutics.com

Or Contact Meris Kott CEO email to info@xtacytherapeutics.com (604) 484-0355

Further information about the Company is available on www.SEDARplus.com under the Company’s profile.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.